Get the Stockscreener App
27.45
1.78%
-0.48
Lenz Therapeutics Inc stock is traded at $27.45, with a volume of 376.28K.
It is down -1.78% in the last 24 hours and down -43.72% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$27.93
Open:
$26.91
24h Volume:
376.28K
Relative Volume:
0.48
Market Cap:
$782.65M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-4.9042
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-10.96%
1M Performance:
-43.72%
6M Performance:
-7.07%
1Y Performance:
-3.51%
1-Day Range:
$26.79
$27.87
1-Week Range:
$26.79
$32.00
52-Week Range:
$16.54
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
27.44 | 845.46M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.88 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.80 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.20 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.99 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.95 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics Inc (LENZ) Q3 2025 Earnings Report Preview: What To Look For - Yahoo Finance
How LENZ Therapeutics Inc. stock reacts to oil pricesWeekly Risk Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Can LENZ Therapeutics Inc. stock maintain operating marginsJuly 2025 Volume & Consistent Growth Equity Picks - newser.com
Is LENZ Therapeutics Inc. stock ready for a breakoutTrade Entry Report & Safe Capital Growth Plans - newser.com
Analyzing drawdowns of LENZ Therapeutics Inc. with statistical toolsMarket Sentiment Review & Long-Term Growth Plans - newser.com
Tools to assess LENZ Therapeutics Inc.’s risk profileWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
Ranking LENZ Therapeutics Inc. among high performing stocks via toolsDay Trade & Daily Technical Stock Forecast Reports - newser.com
Has LENZ Therapeutics Inc. formed a bullish divergenceJuly 2025 Gainers & Weekly Sector Rotation Insights - newser.com
Why LENZ Therapeutics Inc. stock remains on watchlistsJuly 2025 Levels & High Accuracy Buy Signal Tips - newser.com
Chart overlay techniques for tracking LENZ Therapeutics Inc.Insider Selling & Stock Portfolio Risk Management - newser.com
Is LENZ Therapeutics Inc. trending in predictive chart modelsJuly 2025 Decliners & Weekly Top Performers Watchlists - newser.com
How LENZ Therapeutics Inc. stock reacts to Fed rate cutsMarket Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com
Combining price and volume data for LENZ Therapeutics Inc.Day Trade & AI Driven Stock Price Forecasts - newser.com
Real time scanner hits for LENZ Therapeutics Inc. explainedJuly 2025 Selloffs & Real-Time Volume Analysis - newser.com
Published on: 2025-11-03 03:22:46 - newser.com
What does recent volatility data suggest for LENZ Therapeutics Inc.Buy Signal & Community Verified Trade Alerts - newser.com
What risks investors should watch in LENZ Therapeutics Inc. stockJuly 2025 Volume & Reliable Price Breakout Alerts - newser.com
Signal strength of LENZ Therapeutics Inc. stock in tech scannersWeekly Stock Analysis & Real-Time Buy Zone Alerts - newser.com
Will LENZ Therapeutics Inc. continue its uptrendJuly 2025 Spike Watch & Real-Time Chart Breakout Alerts - newser.com
Analyzing net buyer seller activity in LENZ Therapeutics Inc.2025 Major Catalysts & Fast Gain Swing Trade Alerts - newser.com
Why LENZ Therapeutics Inc. stock is trending among retail tradersGlobal Markets & Daily Chart Pattern Signal Reports - newser.com
Is LENZ Therapeutics Inc. stock a buy in volatile marketsWeekly Trade Report & Low Risk High Reward Trade Ideas - newser.com
Will LENZ Therapeutics Inc. stock see PE expansionWeekly Profit Summary & Fast Exit and Entry Strategy Plans - newser.com
How LENZ Therapeutics Inc. stock trades before earningsPortfolio Gains Report & High Win Rate Trade Alerts - newser.com
How interest rate cuts could boost LENZ Therapeutics Inc. stockShort Setup & Smart Swing Trading Alerts - newser.com
Why LENZ Therapeutics Inc. stock remains undervaluedQuarterly Earnings Summary & Community Consensus Stock Picks - newser.com
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Sep 30 '25 |
Sale |
46.01 |
92,030 |
4,234,695 |
764,127 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
42.23 |
90,654 |
3,828,632 |
1,183,543 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
42.23 |
44,650 |
1,885,724 |
856,157 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 25 '25 |
Sale |
39.54 |
52,419 |
2,072,738 |
1,321,640 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
47,443 |
1,850,891 |
1,274,197 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
26,161 |
1,050,392 |
1,374,059 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 25 '25 |
Sale |
39.54 |
25,818 |
1,020,888 |
924,175 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
23,368 |
911,655 |
900,807 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
12,885 |
517,356 |
949,993 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 15 '25 |
Sale |
39.50 |
145,051 |
5,729,514 |
1,430,848 |
1.71%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):